The Inflation Reduction Act: Is it Good or Bad for Drug Innovation?
In August 2022, the United States took a significant legislative step with the passage of the Inflation Reduction Act (IRA). Among the various sectors impacted, the pharmaceutical industry is poised to be particularly affected as it stands at a critical juncture, especially concerning prescription drug pricing reform. This legislation brings to the fore a vital […]
M&A After the FTC’s Noncompete Ban: Can Garden Leave Structures Fill the Gap?
In a move that’s set to reshape the landscape of mergers and acquisitions (M&A), the Federal Trade Commission (FTC) recently decided to ban noncompete agreements, an act that has sent ripples through the corporate world. Traditionally, noncompete clauses had been a staple in mitigating risks associated with M&A activities, especially concerning the retention of key […]
A&M CTG’s Insight-Oriented Approach Will Disrupt M&A Industry Norms
In the realm of corporate transactions and consulting, a seismic shift is on the horizon, one that promises to challenge the status quo and redefine industry benchmarks. The epicenter of this impending revolution? Alvarez & Marsal’s (A&M) Corporate Transaction Group (CTG) and our insight-oriented approach to value creation. Our innovative strategy stands in stark contrast […]